Mesenchymal stem cells in progression and treatment of cancers

Abstract

Mesenchymal stem or stromal cells (MSCs) from bone marrow or local tissues are recruited to stroma of almost all types of cancers during initiation and/or progression of cancer. The recruited MSCs and their derivative cancer-associated fibroblasts interact with cancer cells to promote stemness, invasion and metastasis of cancer cells. Targeting these cancer-recruited MSCs and/or the interaction between MSCs and cancer cells are promising strategies to improve cancer therapy. On the other hand, the unique tumor-homing capacity of MSCs makes them a promising vehicle to deliver various anti-cancer agents. This review summarized the recent advancement of our understanding on the interaction between MSCs and cancer cells, as well as the potential of MSCs for cancer therapy.

Keywords

mesenchymal stem or stromal cells / cancer / cancer-associated fibroblasts / gene therapy / cell therapy

References

[1] BolontradeM F, SgangaL, PiaggioE, VialeD L, SorrentinoM A, RobinsonA, SevleverG, GarcíaM G, MazzoliniG, PodhajcerO L (2012). A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus. Stem Cells Dev, 21(14): 2689–2702

[2] BrunoS, CollinoF, DeregibusM C, GrangeC, TettaC, CamussiG (2013). Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev, 22(5): 758–771

[3] CarreroR, CerradaI, LledóE, DopazoJ, García-GarcíaF, RubioM P, TriguerosC, DorronsoroA, Ruiz-SauriA, MonteroJ A, SepúlvedaP (2012). IL1β induces mesenchymal stem cells migration and leucocyte chemotaxis through NF-κB. Stem Cell Rev, 8(3): 905–916

[4] CastletonA, DeyA, BeatonB, PatelB, AucherA, DavisD M, FieldingA K (2014). Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood, 123(9): 1327–1335

[5] CavarrettaI T, AltanerovaV, MatuskovaM, KucerovaL, CuligZ, AltanerC (2010). Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther, 18(1): 223–231

[6] ChaturvediP, GilkesD M, WongC C, LuoW, ZhangH, WeiH, TakanoN, SchitoL, LevchenkoA, SemenzaG L, and the Kshitiz (2013). Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. J Clin Invest, 123(1): 189–205

[7] ChenM Y, LieP C, LiZ L, WeiX (2009). Endothelial differentiation of Wharton’s jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells. Exp Hematol, 37(5): 629–640

[8] De BoeckA, PauwelsP, HensenK, RummensJ L, WestbroekW, HendrixA, MaynardD, DenysH, LambeinK, BraemsG, GespachC, BrackeM, De WeverO (2013). Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut, 62(4): 550–560

[9] de PeppoG M, Marcos-CamposI, KahlerD J, AlsalmanD, ShangL, Vunjak-NovakovicG, MaroltD (2013). Engineering bone tissue substitutes from human induced pluripotent stem cells. Proc Natl Acad Sci USA, 110(21): 8680–8685

[10] Di StasiA, TeyS K, DottiG, FujitaY, Kennedy-NasserA, MartinezC, StraathofK, LiuE, DurettA G, GrilleyB, LiuH, CruzC R, SavoldoB, GeeA P, SchindlerJ, KranceR A, HeslopH E, SpencerD M, RooneyC M, BrennerM K (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med, 365(18): 1673–1683

[11] DuchiS, SotgiuG, LucarelliE, BallestriM, DozzaB, SantiS, GuerriniA, DambruosoP, GianniniS, DonatiD, FerroniC, VarchiG (2013). Mesenchymal stem cells as delivery vehicle of porphyrin loaded nanoparticles: effective photoinduced in vitro killing of osteosarcoma. J Control Release, 168(2): 225–237

[12] DvorakH F (1986). Tumors: wounds that do not heal.Similarities between tumor stroma generation and wound healing. N Engl J Med, 315(26): 1650–1659

[13] El-HaibiC P, BellG W, ZhangJ, CollmannA Y, WoodD, ScherberC M, CsizmadiaE, MarianiO, ZhuC, CampagneA, TonerM, BhatiaS N, IrimiaD, Vincent-SalomonA, KarnoubA E (2012). Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci USA, 109(43): 17460–17465

[14] ErlerJ T, BennewithK L, CoxT R, LangG, BirdD, KoongA, LeQ T, GiacciaA J (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell, 15(1): 35–44

[15] García-CastroJ, AlemanyR, CascallóM, Martínez-QuintanillaJ, ArrieroM M, LassalettaA, MaderoL, RamírezM (2010). Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. Cancer Gene Ther, 17(7): 476–483

[16] GoldenbergD M, GoldD V, LooM, LiuD, ChangC H, JaffeE S (2013). Horizontal transmission of malignancy: in-vivo fusion of human lymphomas with hamster stroma produces tumors retaining human genes and lymphoid pathology. PLoS ONE, 8(2): e55324

[17] GrisendiG, BussolariR, CafarelliL, PetakI, RasiniV, VeronesiE, De SantisG, SpanoC, TagliazzucchiM, Barti-JuhaszH, ScarabelliL, BambiF, FrassoldatiA, RossiG, CasaliC, MorandiU, HorwitzE M, PaolucciP, ConteP, DominiciM (2010). Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res, 70(9): 3718–3729

[18] HoI A, TohH C, NgW H, TeoY L, GuoC M, HuiK M, LamP Y (2013). Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Stem Cells, 31(1): 146–155

[19] HongH S, LeeJ, LeeE, KwonY S, LeeE, AhnW, JiangM H, KimJ C, SonY (2009). A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells. Nat Med, 15(4): 425–435

[20] HoughtonJ, StoicovC, NomuraS, RogersA B, CarlsonJ, LiH, CaiX, FoxJ G, GoldenringJ R, WangT C (2004). Gastric cancer originating from bone marrow-derived cells. Science, 306(5701): 1568–1571

[21] IpJ E, WuY, HuangJ, ZhangL, PrattR E, DzauV J (2007). Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell, 18(8): 2873–2882

[22] JacobsenB M, HarrellJ C, JedlickaP, BorgesV F, Varella-GarciaM, HorwitzK B (2006). Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res, 66(16): 8274–8279

[23] JohannP D, VaeglerM, GiesekeF, MangP, Armeanu-EbingerS, KlubaT, HandgretingerR, MüllerI (2010). Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer, 10(1): 501

[24] JungY, KimJ K, ShiozawaY, WangJ, MishraA, JosephJ, BerryJ E, McGeeS, LeeE, SunH, WangJ, JinT, ZhangH, DaiJ, KrebsbachP H, KellerE T, PientaK J, TaichmanR S (2013). Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun, 4: 1795

[25] KarnoubA E, DashA B, VoA P, SullivanA, BrooksM W, BellG W, RichardsonA L, PolyakK, TuboR, WeinbergR A (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449(7162): 557–563

[26] KhakooA Y, PatiS, AndersonS A, ReidW, ElshalM F, RoviraI I, NguyenA T, MalideD, CombsC A, HallG, ZhangJ, RaffeldM, RogersT B, Stetler-StevensonW, FrankJ A, ReitzM, FinkelT (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med, 203(5): 1235–1247

[27] KiddS, CaldwellL, DietrichM, SamudioI, SpaethE L, WatsonK, ShiY, AbbruzzeseJ, KonoplevaM, AndreeffM, MariniF C (2010). Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy, 12(5): 615–625

[28] KimS W, KimS J, ParkS H, YangH G, KangM C, ChoiY W, KimS M, JeunS S, SungY C (2013). Complete regression of metastatic renal cell carcinoma by multiple injections of engineered mesenchymal stem cells expressing dodecameric TRAIL and HSV-TK. Clin Cancer Res, 19(2): 415–427

[29] KinnairdT, StabileE, BurnettM S, LeeC W, BarrS, FuchsS, EpsteinS E (2004). Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res, 94(5): 678–685

[30] KitadaiY, SasakiT, KuwaiT, NakamuraT, BucanaC D, HamiltonS R, FidlerI J (2006). Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer, 119(11): 2567–2574

[31] Kolluri,K.K., Laurent,G.J., and Janes,S.M. (2013). Mesenchymal stem cells as vectors for lung cancer therapy. Respiration; international review of thoracic diseases85, 443–451.

[32] KomlevV S, MastrogiacomoM, PeyrinF, CanceddaR, RustichelliF (2009). X-ray synchrotron radiation pseudo-holotomography as a new imaging technique to investigate angio- and microvasculogenesis with no usage of contrast agents. Tissue Eng Part C Methods, 15(3): 425–430

[33] KramanM, BambroughP J, ArnoldJ N, RobertsE W, MagieraL, JonesJ O, GopinathanA, TuvesonD A, FearonD T (2010). Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science, 330(6005): 827–830

[34] KrausgrillB, VantlerM, BurstV, RathsM, HalbachM, FrankK, SchynkowskiS, SchenkK, HeschelerJ, RosenkranzS, Müller-EhmsenJ (2009). Influence of cell treatment with PDGF-BB and reperfusion on cardiac persistence of mononuclear and mesenchymal bone marrow cells after transplantation into acute myocardial infarction in rats. Cell Transplant, 18(8): 847–853

[35] KucerovaL, AltanerovaV, MatuskovaM, TyciakovaS, AltanerC (2007). Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res, 67(13): 6304–6313

[36] KucerovaL, MatuskovaM, PastorakovaA, TyciakovaS, JakubikovaJ, BohovicR, AltanerovaV, AltanerC (2008). Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J Gene Med, 10(10): 1071–1082

[37] LarsonB L, YlostaloJ, LeeR H, GregoryC, ProckopD J (2010). Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells. Tissue Eng Part A, 16(11): 3385–3394

[38] LazovaR, LabergeG S, DuvallE, SpoelstraN, KlumpV, SznolM, CooperD, SpritzR A, ChangJ T, PawelekJ M (2013). A melanoma brain metastasis with a donor-patient hybrid genome following bone marrow transplantation: first evidence for fusion in human cancer. PLoS ONE, 8(6): e66731

[39] LeeR H, PulinA A, SeoM J, KotaD J, YlostaloJ, LarsonB L, Semprun-PrietoL, DelafontaineP, ProckopD J (2009a). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell, 5(1): 54–63

[40] LeeR H, SeoM J, PulinA A, GregoryC A, YlostaloJ, ProckopD J (2009b). The CD34-like protein PODXL and alpha6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice. Blood, 113(4): 816–826

[41] LeeR H, YoonN, ReneauJ C, ProckopD J (2012). Preactivation of human MSCs with TNF-α enhances tumor-suppressive activity. Cell Stem Cell, 11(6): 825–835

[42] LesleyJ, GálI, MahoneyD J, CordellM R, RuggM S, HymanR, DayA J, MikeczK (2004). TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem, 279(24): 25745–25754

[43] LiH J, ReinhardtF, HerschmanH R, WeinbergR A (2012). Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov, 2(9): 840–855

[44] LinR, MaH, DingZ, ShiW, QianW, SongJ, HouX (2013). Bone marrow-derived mesenchymal stem cells favor the immunosuppressive T cells skewing in a Helicobacter pylori model of gastric cancer. Stem Cells Dev, 22(21): 2836–2848

[45] LiuS, GinestierC, OuS J, ClouthierS G, PatelS H, MonvilleF, KorkayaH, HeathA, DutcherJ, KleerC G, JungY, DontuG, TaichmanR, WichaM S (2011a). Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res, 71(2): 614–624

[46] LiuY, HanZ P, ZhangS S, JingY Y, BuX X, WangC Y, SunK, JiangG C, ZhaoX, LiR, GaoL, ZhaoQ D, WuM C, WeiL X (2011b). Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J Biol Chem, 286(28): 25007–25015

[47] LoebingerM R, EddaoudiA, DaviesD, JanesS M (2009). Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res, 69(10): 4134–4142

[48] LoebingerM R, JanesS M (2010). Stem cells as vectors for antitumour therapy. Thorax, 65(4): 362–369

[49] LuY R, YuanY, WangX J, WeiL L, ChenY N, CongC, LiS F, LongD, TanW D, MaoY Q, ZhangJ, LiY P, ChengJ Q (2008). The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther, 7(2): 245–251

[50] MaderE K, MaeyamaY, LinY, ButlerG W, RussellH M, GalanisE, RussellS J, DietzA B, PengK W (2009). Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res, 15(23): 7246–7255

[51] Martinez-QuintanillaJ, BhereD, HeidariP, HeD, MahmoodU, ShahK (2013). Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors. Stem Cells, 31(8): 1706–1714

[52] MarxJ (2008). Cancer biology.All in the stroma: cancer’s Cosa Nostra. Science, 320(5872): 38–41

[53] MatuskovaM, HlubinovaK, PastorakovaA, HunakovaL, AltanerovaV, AltanerC, KucerovaL (2010). HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett, 290(1): 58–67

[54] MiZ, BhattacharyaS D, KimV M, GuoH, TalbotL J, KuoP C (2011). Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis, 32(4): 477–487

[55] MiZ, GuoH, RussellM B, LiuY, SullengerB A, KuoP C (2009). RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther, 17(1): 153–161

[56] MishraP J, MishraP J, HumeniukR, MedinaD J, AlexeG, MesirovJ P, GanesanS, GlodJ W, BanerjeeD (2008). Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res, 68(11): 4331–4339

[57] NasefA, MathieuN, ChapelA, FrickJ, FrançoisS, MazurierC, BoutarfaA, BouchetS, GorinN C, ThierryD, FouillardL (2007). Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation, 84(2): 231–237

[58] PatelS A, MeyerJ R, GrecoS J, CorcoranK E, BryanM, RameshwarP (2010). Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol, 184(10): 5885–5894

[59] PeinadoH, AlečkovićM, LavotshkinS, MateiI, Costa-SilvaB, Moreno-BuenoG, Hergueta-RedondoM, WilliamsC, García-SantosG, GhajarC, Nitadori-HoshinoA, HoffmanC, BadalK, GarciaB A, CallahanM K, YuanJ, MartinsV R, SkogJ, KaplanR N, BradyM S, WolchokJ D, ChapmanP B, KangY, BrombergJ, LydenD (2012). Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med, 18(6): 883–891

[60] PeterM E (2009). Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle, 8(6): 843–852

[61] QiaoL, XuZ L, ZhaoT J, YeL H, ZhangX D (2008). Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett, 269(1): 67–77

[62] QuanteM, TuS P, TomitaH, GondaT, WangS S, TakashiS, BaikG H, ShibataW, DipreteB, BetzK S, FriedmanR, VarroA, TyckoB, WangT C (2011). Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell, 19(2): 257–272

[63] RappaG, MercapideJ, LoricoA (2012). Spontaneous formation of tumorigenic hybrids between breast cancer and multipotent stromal cells is a source of tumor heterogeneity. Am J Pathol, 180(6): 2504–2515

[64] RenC, KumarS, ChandaD, ChenJ, MountzJ D, PonnazhaganS (2008a). Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells, 26(9): 2332–2338

[65] RenC, KumarS, ChandaD, KallmanL, ChenJ, MountzJ D, PonnazhaganS (2008b). Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther, 15(21): 1446–1453

[66] SageE K, KolluriK K, McNultyK, LourencoS D, KalberT L, OrdidgeK L, DaviesD, Gary LeeY C, GiangrecoA, JanesS M (2014). Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax,

[67] SánchezL, Gutierrez-ArandaI, LigeroG, RubioR, Muñoz-LópezM, García-PérezJ L, RamosV, RealP J, BuenoC, RodríguezR, DelgadoM, MenendezP (2011). Enrichment of human ESC-derived multipotent mesenchymal stem cells with immunosuppressive and anti-inflammatory properties capable to protect against experimental inflammatory bowel disease. Stem Cells, 29(2): 251–262

[68] SasportasL S, KasmiehR, WakimotoH, HingtgenS, van de WaterJ A, MohapatraG, FigueiredoJ L, MartuzaR L, WeisslederR, ShahK (2009). Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA, 106(12): 4822–4827

[69] SeoK W, LeeH W, OhY I, AhnJ O, KohY R, OhS H, KangS K, YounH Y (2011a). Anti-tumor effects of canine adipose tissue-derived mesenchymal stromal cell-based interferon-β gene therapy and cisplatin in a mouse melanoma model. Cytotherapy, 13(8): 944–955

[70] SeoS H, KimK S, ParkS H, SuhY S, KimS J, JeunS S, SungY C (2011b). The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther, 18(5): 488–495

[71] ShangguanL, TiX, KrauseU, HaiB, ZhaoY, YangZ, LiuF (2012). Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem Cells, 30(12): 2810–2819

[72] ShimodaM, MellodyK T, OrimoA (2010). Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol, 21(1): 19–25

[73] ShinagawaK, KitadaiY, TanakaM, SumidaT, OnoyamaM, OhnishiM, OharaE, HigashiY, TanakaS, YasuiW, ChayamaK (2013). Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer. Int J Cancer, 132(4): 813–823

[74] SongC, LiG (2011). CXCR4 and matrix metalloproteinase-2 are involved in mesenchymal stromal cell homing and engraftment to tumors. Cytotherapy, 13(5): 549–561

[75] SpaethE L, LabaffA M, TooleB P, KloppA, AndreeffM, MariniF C (2013). Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res, 73(17): 5347–5359

[76] StroncekD, BerlyneD, FoxB, GeeA, HeimfeldS, LindbladR, LoperK, McKennaD Jr, RooneyC, SabatinoM, WagnerE, WhitesideT, WoodD, Heath-MondoroT (2010). Developments in clinical cell therapy. Cytotherapy, 12(3): 425–428

[77] SuzukiK, SunR, OriguchiM, KanehiraM, TakahataT, ItohJ, UmezawaA, KijimaH, FukudaS, SaijoY (2011). Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med, 17(7-8): 579–587

[78] TokarE J, DiwanB A, WaalkesM P (2010). Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype. Environ Health Perspect, 118(1): 108–115

[79] Toledano FurmanN E, Lupu-HaberY, BronshteinT, KanetiL, LetkoN, WeinsteinE, BaruchL, MachlufM (2013). Reconstructed stem cell nanoghosts: a natural tumor targeting platform. Nano Lett, 13(7): 3248–3255

[80] UchiboriR, OkadaT, ItoT, UrabeM, MizukamiH, KumeA, OzawaK (2009). Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J Gene Med, 11(5): 373–381

[81] VarnatF, DuquetA, MalerbaM, ZbindenM, MasC, GervazP, Ruiz i AltabaA (2009). Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol Med, 1(6-7): 338–351

[82] ViswanathanS, KeatingA, DeansR, HemattiP, ProckopD, StroncekD F, StaceyG, WeissD J, MasonC, RaoM S (2014). Soliciting Strategies for Developing Cell-Based Reference Materials to Advance MSC Research and Clinical Translation. Stem Cells Dev: 140310064908006

[83] WangM L, PanC M, ChiouS H, ChenW H, ChangH Y, LeeO K, HsuH S, WuC W (2012). Oncostatin m modulates the mesenchymal-epithelial transition of lung adenocarcinoma cells by a mesenchymal stem cell-mediated paracrine effect. Cancer Res, 72(22): 6051–6064

[84] WuS, JuG Q, DuT, ZhuY J, LiuG H (2013). Microvesicles derived from human umbilical cord Wharton’s jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo. PLoS ONE, 8(4): e61366

[85] WuY, ZhouB P (2010). Snail: More than EMT. Cell Adhes Migr, 4(2): 199–203

[86] XinH, KanehiraM, MizuguchiH, HayakawaT, KikuchiT, NukiwaT, SaijoY (2007). Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells, 25(7): 1618–1626

[87] XuM H, GaoX, LuoD, ZhouX D, XiongW, LiuG X (2014). EMT and acquisition of stem cell-like properties are involved in spontaneous formation of tumorigenic hybrids between lung cancer and bone marrow-derived mesenchymal stem cells. PLoS ONE, 9(2): e87893

[88] XuS, MenuE, De BeckerA, Van CampB, VanderkerkenK, Van RietI (2012). Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells, 30(2): 266–279

RIGHTS & PERMISSIONS

Higher Education Press and Springer-Verlag Berlin Heidelberg